Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvingtrans Regulatory News (AVG)

Share Price Information for Avingtrans (AVG)

Share Price is delayed by 15 minutes
Get Live Data
650.00    0.00 (0.00%)
Bid:
640.00
Ask:
660.00
Spread: 20.00 (3.125%)
Market Cap: £219.22m
AVG Live PriceLast checked at - London Stock Exchange

Intraday Avingtrans Share Chart

Board Appointment

19 Aug 2008 07:00

Embargoed Release: 07:00 hrs Tuesday 19 August 2008

Avingtrans Plc (`Avingtrans' or the `Group') Board Appointment and Board changes

Avingtrans Plc, the designer, manufacturer and supplier of critical components and associated services to the medical, energy, industrial and global aerospace sectors, is delighted to announce the appointment of Stephen ("Steve") McQuillan as chief executive officer. The Group believes the appointment of this highly regarded and experienced figure will bolster the strength of the management team as Avingtrans continues to exploit the excellent prospects in its respective markets going forward.

Steve McQuillan, age 47, will commence his duties as CEO from 1st October 2008. He brings extensive expertise to the Group from the engineering and technology sectors as he was previously managing director of Serco Defence Operations, a leading integrated service solutions provider to the worldwide defence and aerospace markets, from 2005 to 2008. Prior to this, Stephen was the managing director of Oxford Instruments Superconductivity Ltd, a subsidiary of Oxford Instruments plc, the designer, manufacturer and support services provider of high technology tools and systems for industry research, space, energy and healthcare sectors.

In conjunction with this appointment, Roger McDowell, who has been acting chief executive and non-executive chairman during the interim period, will revert to non-executive chairman as from 1st October 2008.

Roger McDowell commented:

"I very much welcome Stephen to the Board of Avingtrans as group chief executive; I am delighted that someone of such a high calibre with a wealth of UK and overseas experience has agreed to join the Group. Stephen has first class knowledge of and expertise in engineering, technology and knowledge transfer markets, which will be invaluable to the Group as we continue to expand our businesses."

Steve McQuillan commented:

"I am looking forward to working with the team at Avingtrans where I see significant opportunities to grow the businesses in its respective markets. The Group has strong technical and commercial capabilities and our aim will be to leverage these over the course of time."

-ENDS-

For further information, please contact:

Avingtrans plc

Roger McDowell, Non-Executive Chairman

Tel: 0115 949 9020

KBC Peel Hunt Ltd (Nominated Adviser & Broker)

Julian BluntDavid AndersonTel: 020 7418 8900Hansard Group Adam ReynoldsTel: 020 7245 1100

In accordance with paragraph (g) of Schedule 2 to the AIM Rules for Companies, the following information is provided:

Current Directorships Past Directorships over last 5 years NPL Management Limited Oxford Instruments Superconductivity Limited Airto Limited Oxford Instruments Superconductivity Holdings Limited Oxford Instruments Molecular Biotools Limited Resonance Instruments Limited

There is no further information in respect of the above appointment required to be disclosed pursuant to paragraph (g) of Schedule 2 to the AIM Rules for Companies.

vendor
Date   Source Headline
19th May 202610:20 amRNSHolding(s) in Company
14th May 202612:26 pmRNSHolding(s) in Company
12th May 20267:00 amRNSAdaptix receives CE Certification
6th May 20264:28 pmRNSHolding(s) in Company
30th Apr 20262:42 pmRNSHolding(s) in Company
30th Apr 20262:41 pmRNSExercise of Options & TVR
24th Apr 20262:54 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSStrong Nuclear Orders for Avingtrans
26th Mar 20267:00 amRNS-RScientific Magnetics Ships 20th Quantum Magnet
4th Mar 20267:00 amRNSHolding(s) in Company
25th Feb 20267:00 amRNSInterim Results
12th Feb 202611:49 amRNSHolding(s) in Company
6th Feb 202610:24 amRNSHolding(s) in Company
27th Jan 20265:42 pmRNSExercise of Options & TVR
21st Jan 20267:00 amRNSTrading Update and Notice of Results
12th Jan 20265:13 pmRNSIssue of Share Options
12th Jan 20267:00 amRNS-RMedical & Industrial Imaging Division Appointment
8th Dec 20252:34 pmRNSNotification of Major Holdings
27th Nov 20251:59 pmRNSResult of AGM - Board Appointment
14th Nov 20258:38 amRNSExercise of Options & PDMR Dealings
10th Nov 20257:00 amRNSAdaptix receives FDA 510(K) clearance
1st Oct 20254:52 pmRNSExercise of Options & Total Voting Rights
1st Oct 20253:32 pmRNSHolding(s) in Company
29th Sep 20257:00 amRNSAppointment of Medical Division CEO
24th Sep 20257:00 amRNSPreliminary results for the year ended 31 May 2025
11th Sep 20258:00 amRNSHolding(s) in Company
2nd Sep 20257:00 amRNSHayward Tyler Secures $16m Nuclear Contracts
28th Aug 20257:00 amRNSBooth Industries secures £8.5m HS2 & TfL contracts
25th Jun 20257:00 amRNSTrading Update and Notice of Results
28th May 20257:00 amRNSTrading Update
26th Feb 20257:00 amRNSInterim Results
13th Feb 20257:00 amRNSBooth Industries secures £4.5m Contract
16th Jan 20257:00 amRNSTrading Update & Notice of Results
21st Nov 20244:09 pmRNSResult of AGM
24th Oct 20249:07 amRNSHolding(s) in Company
25th Sep 20247:00 amRNSPreliminary results for the year ended 31 May 2024
3rd Jul 20247:00 amRNSPDMR Dealings
19th Jun 20247:00 amRNSTrading Update and Notice of Results
26th Mar 202411:15 amRNSPDMR Dealings
21st Mar 20245:15 pmRNSExercise of Options, PDMR Dealings & TVR
20th Mar 20243:39 pmRNSHolding(s) in Company
4th Mar 20246:10 pmRNSPDMR Dealings
28th Feb 20247:00 amRNSInterim Results
18th Jan 20247:00 amRNSTrading Update and Notice of Results
15th Dec 20233:00 pmRNSExercise of Options & TVR
4th Dec 20237:00 amRNSMagnetica Limited appoints US distributor
22nd Nov 20237:00 amRNSEmployee & PDMR Share Incentive Awards
16th Nov 20232:20 pmRNSResult of AGM
13th Nov 20237:00 amRNSHayward Tyler Contract Win
11th Oct 20237:00 amRNSContract Wins

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.